Yesterday, Wyeth Pharmaceuticals, a division of Wyeth (WYE), announced data from a placebo-controlled late-stage study of its drug candidate bazedoxifene 20 mg in postmenopausal women with osteoporosis. The results indicated that women who took bazedoxifene had a lower risk of new fractures to their vertebrae. As a reminder, 20 mg and 40 mg doses of the [...] (WYE) Wyeth Pharmaceuticals Reports Positive Drug Data